Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7381 to 7395 of 8314 results

  1. Epilepsy in children and young people (QS27)

    This quality standard has been updated and replaced by NICE quality standard 211. 

    Quality standard
    Published
    28 February 2013

  2. Venous thromboembolism in adults: diagnosis and management (QS29)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Quality standard
    Last updated
    25 January 2021

  3. Venous thromboembolism in adults: reducing the risk in hospital (QS3)

    This quality standard has been updated and replaced by NICE quality standard QS201.

    Quality standard
    Last updated
    21 March 2018

  4. Dementia: independence and wellbeing (QS30)

    This quality standard has been updated and replaced by NICE quality standard 184. 

    Quality standard
    Published
    3 April 2013

  5. Moderately to severely active ulcerative colitis: adalimumab (ESNM6)

    This evidence summary has been replaced by NICE technology appraisal guidance 329.

    Evidence summary
    Published
    2 November 2012

  6. Type 2 diabetes: dulaglutide (ESNM59)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    16 June 2015

  7. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1103.

    Technology appraisal guidance
    Published
    12 July 2023

  8. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

    This evidence summary has been withdrawn because licensed products are now available.

    Evidence summary
    Published
    4 January 2013

  9. Key therapeutic topics – Medicines management options for local implementation: Interim process statement (PMG7)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.

  10. Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.

  11. Process manual for the endorsement of guidance and quality standard support resources (PMG29)

    The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.

  12. Developing NICE guidelines: how to get involved (PMG22)

    October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.

  13. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

    This guideline has been updated and replaced by NICE guideline NG101.

    Technology appraisal guidance
    Published
    22 November 2006

  14. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)

    This guideline has been updated and replaced by NICE guideline NG101.

    Technology appraisal guidance
    Published
    23 August 2006

  15. Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)

    This guideline has been updated and replaced by NICE guideline NG101.

    Technology appraisal guidance
    Published
    27 September 2006